In non-small cell lung cancer patients, immunoPET with 89Zr-nivolumab enabled the noninvasive quantification of PD-1/ PD-L1 tumor expression, demonstrating PD-L1 tumor expression heterogeneity between metastases of the same patient and among different patients [89]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.